Fintel reports that on November 7, 2025, Canaccord Genuity maintained coverage of Insulet (NasdaqGS:PODD) with a Buy ...
4d
Insulet (PODD): Evaluating Valuation After Q3 2025 Results, Upgraded Guidance, and Omnipod Expansion
Insulet (PODD) delivered third-quarter 2025 results that surpassed analyst predictions for both revenue and earnings. This outcome was due to meaningful expansion in its Omnipod insulin delivery ...
Zacks Investment Research on MSN
Insulet (PODD) Upgraded to Strong Buy: Here's What You Should Know
Insulet (PODD) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...
Insulet Corporation (NASDAQ:PODD) is one of the Best Long Term Growth Stocks to Buy Now. On September 17, Truist Securities analyst Richard Newitter reiterated a “Buy” rating on the company’s stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback